2021
Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non–Inflammatory Bowel Disease Controls
Krugliak Cleveland N, Rai V, El Jurdi K, Rao S, Giurcanu M, Rubin D. Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non–Inflammatory Bowel Disease Controls. Gastroenterology 2021, 162: 331-333.e1. PMID: 34597674, PMCID: PMC8678316, DOI: 10.1053/j.gastro.2021.09.052.Peer-Reviewed Original ResearchEndoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes
Akiyama S, Ollech J, Rai V, Glick L, Yi Y, Traboulsi C, Runde J, Cohen R, Skowron K, Hurst R, Umanskiy K, Shogan B, Hyman N, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Rubin D. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clinical Gastroenterology And Hepatology 2021, 20: 293-302.e9. PMID: 33549868, PMCID: PMC8339185, DOI: 10.1016/j.cgh.2021.02.010.Peer-Reviewed Original ResearchConceptsIleal pouch-anal anastomosisDiffuse inflammationPouch excisionSignificant contributing factorLimb involvementAnti-tumor necrosis factor drugsCox proportional hazards modelPouch-anal anastomosisFuture interventional studiesInflammatory bowel diseasePattern of inflammationHand-sewn anastomosisBody mass indexClostridioides difficile infectionLog-rank testContributing factorProportional hazards modelLogistic regression analysisEndoscopic patternsExtensive colitisIleostomy takedownPouch bodyPouch survivalBowel diseaseCommon complication
2020
Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study
Yvellez O, Rai V, Sossenheimer P, Hart J, Turner J, Weber C, Jurdi K, Rubin D. Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflammatory Bowel Diseases 2020, 27: 203-206. PMID: 32152624, PMCID: PMC7813748, DOI: 10.1093/ibd/izaa047.Peer-Reviewed Original ResearchConceptsCumulative inflammatory burdenDevelopment of CRNHistological inflammatory activityColorectal neoplasiaUC patientsUlcerative colitisCRN patientsHistologic inflammationSurveillance intervalsRisk of CRNLow-grade dysplasiaMaximum severitySt. Mark's HospitalCase-control cohortInflammatory burdenInflammatory indexDisease durationInflammatory activityChronic inflammationIndefinite dysplasiaColorectal cancerSurveillance episodesPatientsInflammationMean severity
2019
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis
Ollech J, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer P, Christensen B, Pekow J, Dalal S, Sakuraba A, Cohen R, Rubin D. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis. Alimentary Pharmacology & Therapeutics 2019, 51: 637-643. PMID: 31875986, DOI: 10.1111/apt.15616.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedCalcineurin InhibitorsColitis, UlcerativeDrug Administration ScheduleDrug ResistanceFemaleFollow-Up StudiesHumansInduction ChemotherapyMaintenance ChemotherapyMaleProgression-Free SurvivalRetrospective StudiesSeverity of Illness IndexSteroidsTreatment OutcomeYoung AdultConceptsSevere steroid-refractory ulcerative colitisSteroid-refractory ulcerative colitisCalcineurin inhibitorsInduction therapyMaintenance therapyUlcerative colitisVedolizumab initiationMedian timeWeek 14Colectomy-free survival ratesSevere steroid-refractory colitisColectomy-free survivalSteroid-refractory colitisVedolizumab maintenance therapyInduction of remissionSerious adverse eventsSevere ulcerative colitisRetrospective observational studyEnd of inductionBiochemical remissionVedolizumab discontinuationClinical remissionPrimary endpointSecondary endpointsAdult patients